Table 1. Baseline demographics of infants born <29 weeks gestational age with the reported number of different Food and Drug Administration (FDA) drugs exposed to (N = 710).

	No FDA drug exposure (N = 493)	Exposed to 1 FDA warned drug (N = 96)	Exposed to 2 FDA warned drugs (N = 90)	Exposed to ≥ 3 FDA warned drugs (N = 31)
Infant characteristics				
[a]Gestational age at birth, weeks, mean (SD)	26.8 [25.9-27.6]	26.1 [25.4-26.9]	25.8 [25.2-26.6]	25.7 [24.8-26.4]
Birth weight, g, median [IQR]	930 [780-1093]	845 [711-980]	750 [678=913]	730 [596-920]
Male, n/total N (%)	269/493 (54.6)	59/96 (61.5)	57/90 (63.3)	20/31 (64.5)
SNAPPE II score, median [IQR]	32.0 [19.0-43.0]	36.0 [24.0-50.0]	42.0 [30.0-52.3]	53.0 [31.0-69.0]
Pregnancy				
Maternal alcohol consumption during pregnancy, n/total N (%)	32/493 (6.5)	7/96 (7.3)	4/90 (4.4)	3/31 (9.7)
Maternal smoking during pregnancy, n/total N (%)	108/493 (21.9)	72/96 (28.1)	14/90 (15.6)	10/31 (32.3)
Maternal recreational drug use during pregnancy, n/total N (%)	31/492 (6.3)	3/96 (3.1)	2/90 (2.2)	0/31 (0.0)
Antenatal corticosteroids, n/total N (%)	434/493 (88.0)	78/96 (81.3)	83/90 (92.2)	27/31 (87.1)
Multiple birth, n/total N (%)	137/493 (27.8)	27/96 (28.1)	36/90 (40.0)	11/31 (35.5)
Birth				
Cesarean delivery, n/total N (%)	273/493 (55.4)	51/96 (53.1)	53/90 (58.9)	18/31 (58.1)
Neonatal diseases				
Bronchopulmonary dysplasia, n/total N (%)	224/482 (46.5)	64/95 (67.4)	78/90 (86.7)	26/31 (93.5)
Necrotizing enterocolitis, n/total N (%)	46/492 (9.3)	26/96 (27.1)	14/90 (15.6)	14/31 (45.2)
Patent ductus arteriosus, n/total N (%)	294/493 (59.6)	72/96 (75.0)	74/90 (82.2)	29/31 (93.5)
Respiratory distress syndrome, n/total N (%)	460/491 (93.7)	94/96 (97.9)	88/90 (97.8)	31/31 (100.0)
Severe IVH (grade ≥3), n/total N (%)	47/492 (9.6)	20/95 (21.1)	15/90 (16.7)	10/31 (32.3)
Confirmed sepsis, n/total N (%)	80/492 (16.3)	37/96 (38.5)	32/90 (35.6)	13/31 (41.9)
Neonatal treatment				
Days in hospital, median [IQR]	76 [61-93]	94 [74-115]	109 [91-124]	122 [105-138]
Days on oxygen support, median [IQR]	55 [22-99]	85 [52-188]	155 [90-240]	173 [82-313]

FDA, Food and Drug Administration; SD, standard deviation; IQR, interquartile range; SNAPPE-II, Score for Neonatal Acute Physiology with Perinatal Extension-II; IVH, intraventricular hemorrhage
[a]Gestational age was adjusted for birth weight, complications of pregnancy, and maternal factors